PlentiPlex™ MSI enables a validated screening for microsatellite instability in Tumors. The test works as an aid to assist in further cancer treatments, which provides more personalised and precise treatment for the individual.
PlentiPlex™ MSI assays are intended for evaluation of impaired mismatch repair (MMR) and the resulting microsatellite instability affecting prognosis and selection of treatment in cancer patients. PlentiPlex™ MSI assays offer two different multiplexed MSI assays for the length analysis of five microsatellite loci. This makes PlentiPlex™ MSI assays valuable stratification tools for assisting cancer treatment planning.
Advantages of PlentiPlex™ MSI:
Simple MSI stratification of solid tumors for treatment guidance
Simplified four-step workflow
Well-known validated loci
Minimal hands-on time
PentaBase systems for analysis
The PlentiPlex™ MSI assays are now designed and validated to be used on BaseTyper™48(PentaBase PCR instrument) and the following instruments:
Rotor-Gene (Qiagen)
MX3000P/3005P (Agilent)
LightCycler® 96 + 480 (Roche)
CFX96TM (Bio-Rad)
ABI 7500/7900HT (Applied Biosystems)
MIC (Bio Molecular Systems)
MyGo Pro (IT-IS Life Science)
